

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1332

Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (nivolumab, ipilimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Beating Bowel Cancer • Black Health Agency • Bladder and Bowel Community • Bowel Cancer Information • Bowel Cancer UK • Cancer Black Care • Cancer Equality • Colostomy Association • Helen Rollason Cancer Charity • IA: Ileostomy and Internal Pouch Support Group • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • BASO – The Association for Cancer 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Promega • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (irinotecan, fluorouracil, oxaliplatin) • Actavis UK (irinotecan, oxaliplatin) • Consilient Health Ltd (fluorouracil) • Hospira UK (irinotecan, fluorouracil, oxaliplatin, raltitrexed) • Medac (folinic acid, fluorouracil, oxaliplatin, irinotecan) • Pfizer (irinotecan) • Sandoz (oxaliplatin)

Stakeholder list for the single technology appraisal of Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1332

Issue date: August 2020

© National Institute for Health and Care Excellence 2020. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
<p>Surgery</p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute for Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Rotherham CCG • NHS Surrey Downs CCG • Welsh Government 	<ul style="list-style-type: none"> • Seacross pharmaceuticals (irinotecan, oxaliplatin) • Servier (Trifluridine–tipiracil) • Sun Pharmaceutical Industries Ltd (oxaliplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel & Cancer Research • Cochrane Colorectal Cancer Group • Guts UK • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Stakeholder list for the single technology appraisal of Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1332

Issue date: August 2020

© National Institute for Health and Care Excellence 2020. All rights reserved.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.